The human epidermal growth factor receptor 2 “HER‐2 or HER‐2/neu” (Figure 6a) has been shown to be over‐expressed in certain types of aggressive breast cancers and thus constitutes a promising vaccine target (Mitri, Constantine, & O'Regan, 2012). This evidence concerns the gene ERBB2 and breast cancer.